SOMATULINE DEPOT Drug Patent Profile

Which patents cover Somatuline Depot, and what generic alternatives are available?

Somatuline Depot is a drug marketed by Ipsen Pharma and is included in one NDA.

The generic ingredient in SOMATULINE DEPOT is lanreotide acetate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lanreotide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Somatuline Depot

A generic version of SOMATULINE DEPOT was approved as lanreotide acetate by INVAGEN PHARMS on December 17^th, 2021.

Summary for SOMATULINE DEPOT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
Clinical Trials:	27
Patent Applications:	483
What excipients (inactive ingredients) are in SOMATULINE DEPOT?	SOMATULINE DEPOT excipients list
DailyMed Link:	SOMATULINE DEPOT at DailyMed

Recent Clinical Trials for SOMATULINE DEPOT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ZonMw: The Netherlands Organisation for Health Research and Development	Phase 4
Erasmus Medical Center	Phase 4
University Hospital, Antwerp	Phase 4

See all SOMATULINE DEPOT clinical trials

Pharmacology for SOMATULINE DEPOT

Drug Class	Somatostatin Analog
Mechanism of Action	Somatostatin Receptor Agonists

US Patents and Regulatory Information for SOMATULINE DEPOT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-001	Aug 30, 2007	AB	RX	Yes	Yes
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-002	Aug 30, 2007	AB	RX	Yes	Yes
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-003	Aug 30, 2007	AB	RX	Yes	Yes

Expired US Patents for SOMATULINE DEPOT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-001	Aug 30, 2007	5,595,760
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-002	Aug 30, 2007	5,595,760
Ipsen Pharma	SOMATULINE DEPOT	lanreotide acetate	SOLUTION;SUBCUTANEOUS	022074-003	Aug 30, 2007	5,595,760

International Patents for SOMATULINE DEPOT

See the table below for patents covering SOMATULINE DEPOT around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0778767	ADMINISTRATION DE COMPOSITIONS MEDICAMENTEUSES SOLIDES (DELIVERY OF SOLID DRUG COMPOSITIONS)
China	101590011
European Patent Office	1475114	Systeme d'injection pour l'administration des compositions pharmaceutiques semisolides pour la libération prolongée des sels peptidiques gelables (Injection system suitable for the administration of semisolid, sustained-release pharmaceutical compositions of gelable peptide salts)
Canada	2198916	ADMINISTRATION DE COMPOSITIONS MEDICAMENTEUSES SOLIDES (DELIVERY OF SOLID DRUG COMPOSITIONS)
Denmark	0778767
Australia	3398195

Supplementary Protection Certificates for SOMATULINE DEPOT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0779805	CA 2002 00032	Denmark
0779805	91037	Luxembourg		91037, EXPIRES: 20160511

Market Dynamics and Financial Trajectory for Somatuline Depot: A Strategic Perspective

Last updated: January 9, 2026

---

Summary

Somatuline Depot (lanreotide) stands as a pivotal therapy in the management of neuroendocrine tumors (NETs) and acromegaly, commanding a specialized niche with expanding indications and evolving market interactions. This report analyzes current market conditions, driving factors, competitive positioning, and financial projections, offering business professionals a comprehensive understanding of its trajectory.

---

Introduction

Somatuline Depot, marketed by Ipsen Pharma, is a long-acting injectable somatostatin analog primarily indicated for midgut neuroendocrine tumors (NETs), pancreatic NETs, and acromegaly. Since its regulatory approval, its market performance reflects both scientific advances and strategic commercial developments. The following analysis delves into market forces, revenues, competitive landscape, R&D investments, and regulatory impacts shaping its future.

---

Market Overview

Global Market Size & Segmentation

Segment	Estimated Revenue (2022)	Projection CAGR (2023-2028)	Notes
Neuroendocrine Tumors	$600 million	6.8%	Dominates sales, primary indication
Acromegaly	$350 million	5.5%	Secondary but growing indication
Other (e.g., carcinoid)	$50 million	4.2%	Niche applications
Total Market	$1 billion	6%	Predominantly driven by NETs demand

Source: IQVIA, 2023; MarketsandMarkets, 2022

Regional Market Distribution

Region	Market Share	Key Trends
North America	50%	Strong adoption due to high NET prevalence and diagnostics
Europe	30%	Regulatory approvals expanding indications
Asia-Pacific	10%	Emerging market with increasing access
Rest of World	10%	Growth potential, limited infrastructure

---

Market Drivers

1. Incidence & Diagnosis of NETs & Acromegaly
NETs incidence has increased approximately 4.3% annually globally, driven by improved detection and awareness, fueling demand for somatostatin analogs [1].

2. Evolving Therapeutic Guidelines
Recent guidelines (e.g., ENETS, NANETS) increasingly endorse somatuline depot as first-line for inoperable or metastatic NETs, elevating market penetration [2].

3. Strategic Expansion & New Indications
Ongoing trials exploring somatuline’s role in adjunct therapies and earlier intervention expand its potential customer base.

4. Competitive Dynamics & Patent Lifecycles
While Lanreotide faces direct competition from octreotide formulations, patent cliffs for older formulations and biosimilar entries influence pricing and market share.

---

Competitive Landscape

Competitor	Product Name	Mechanism/Indication(s)	Estimated Market Share (2022)	Notes
Ipsen	Somatuline Depot (lanreotide)	NETs, acromegaly	60%	Leader in long-acting analogs
Novartis (Sandoz)	Seprafilm (biosimilar)	Biosimilar for lanreotide	15%	Price competition influencing market dynamics
Novartis (Somatuline Autogel/Octreotide)	Octreotide LAR	NETs, acromegaly	20%	Major competitor with similar indications
Others	Multiple biosimilars	Various	5%	Emerging biosimilar landscape

Note: Ipsen maintains a dominant share owing to early market entry and robust clinical evidence.

---

Financial Trajectory Analysis

Revenue Growth Trends

Year	Revenue (USD million)	CAGR (2018-2022)	Key Factors
2018	$420	—	Initial launch success, expanding indications
2019	$470	6%	Increased approvals, market expansion
2020	$500	3.2%	COVID-19 pandemic impacts; resilient growth
2021	$565	13%	Post-pandemic rebound, new approvals
2022	$600	6.2%	Continued expansion, price management

Source: Ipsen Annual Reports, 2022

Forecasted Financial Trajectory (2023-2028)

Year	Predicted Revenue (USD million)	Assumed CAGR	Notes
2023	$640	6.7%	Launch of expanded indications, market stabilization
2024	$680	6.3%	Competitive pressure mitigated by clinical data and new markets
2025	$730	7.4%	Entry into emerging markets, biosimilar competition stabilizes
2026	$780	6.8%	Greater adoption for acromegaly, optimized dosing protocols
2027	$830	6.4%	Possible new indications, ongoing clinical trials
2028	$890	7.3%	Market growth driven by continued diagnosis increases

Assumptions: Steady growth driven by new approvals, optimized treatment algorithms, and expanding markets. Biosimilar impact is partially offset by brand loyalty and efficacy profiles.

---

Regulatory & Policy Impact

1. Approvals & Label Expansion
Recent FDA and EMA approvals for second-line indications and broader patient populations enhance market potential.

2. Pricing & Reimbursement Policies
Reimbursement remains robust in high-income markets; however, biosimilar penetration pressures pricing strategies globally.

3. Market Access in Emerging Economies
New policies to increase access, aligned with global health initiatives, are expected to facilitate adoption.

---

Deep Comparison: Somatuline Depot vs. Competitors

Aspect	Somatuline Depot	Octreotide LAR	Biosimilars
Mechanism of Action	Slow-release lanreotide	Long-acting octreotide	Similar to originator, lower cost
Dosing Interval	Every 4 weeks	Every 4 weeks	Similar
Indication Spectrum	NETs, acromegaly	NETs, acromegaly, VIPomas	Varies; primarily specialized
Market Share (2022)	60%	20%	15%
Pricing Strategy	Premium, reflects clinical efficacy	Competitive	Significantly lower
Regulatory Status	Approved in major markets	Approved globally	Approved in various jurisdictions

Note: Differentiation is driven by clinical data, dosing flexibility, and patient tolerability.

---

Key Market Trends & Challenges

Trend	Impact	Challenges
Growing NET Prevalence	Expanding patient base; increased market size	Need for early diagnosis and targeted therapies
Biosimilar Entry	Cost containment; pressure on prices	Maintaining brand loyalty and market share
Clinical Trials & New Indications	Potential pipeline expansions; increased revenues	Long development timelines and regulatory hurdles
Market Consolidation	Larger players expanding portfolio; strategic acquisitions	Reduced competition, tighter margins

---

FAQs

1. What factors most influence the revenue growth of somatuline depot?
Market expansion through indication broadening, increased NET diagnosis rates, regulatory approvals, and competitive positioning significantly influence revenue. Pricing strategies and biosimilar entries also impact margins and growth.

2. How do biosimilars affect somatuline depot’s market share?
Biosimilars offer lower-cost alternatives, exerting downward pressure on prices. Ipsen's brand loyalty and clinical efficacy help maintain market share, but patient and provider preferences for cost-efficient options are challenging.

3. What regulatory trends could impact the future of somatuline depot?
Most influential are approvals of new indications, pricing and reimbursement policies, and biosimilar regulations. Rapid approvals and expanded indications promise growth; restrictive policies may hinder sales.

4. How does somatuline depot compare financially to its competitors?
It commands a premium due to extensive clinical data supporting efficacy and tolerability, translating into higher revenue per patient, despite competitive pressure from biosimilars and octreotide.

5. What strategies should companies consider to maximize market potential for somatuline depot?
Investing in clinical trials for new indications, optimizing pricing, expanding global access especially in emerging markets, and strategic partnerships are key.

---

Key Takeaways

• Market growth for somatuline depot is projected at approximately 6-7% CAGR through 2028, driven by increasing NET and acromegaly diagnoses.
• Ipsen’s early market entry and comprehensive clinical data secure its dominant position amid biosimilar threats.
• Regulatory approvals for expanded indications and regional reimbursement policies are critical levers for growth.
• Pricing strategies need balancing between premium positioning based on efficacy and competitive pressure from biosimilars.
• Emerging markets present significant opportunity, contingent on policies improving access and affordability.

---

References

[1] Yao, J.C., et al. (2021). Incidence, Diagnosis, and Management of Neuroendocrine Tumors. Journal of Clinical Oncology.
[2] ENETS Guidelines (2022). Management of Gastroenteropancreatic Neuroendocrine Tumors. European Neuroendocrine Tumor Society.

---

This comprehensive analysis provides business professionals with an authoritative and data-driven understanding of somatuline depot’s current market situation and future financial trajectory.